Leap tumbles on discontinuation of gastric cancer treatment trials

Cypherpunk Technologies

28/01/2025 12:45

** Shares of drug developer Leap Therapeutics  LPTX.O  fall
67.1% to 74 cents premarket 
    ** Co says it will not move forward with late-stage trials
of its drug, sirexatamab, in patients with gastric cancer
    ** Says drug will show negative results for ongoing
mid-stage trial's main goal of progression free survival when
study completes 
    ** Will explore partnership opportunities to test
sirexatamab in combination with a type of cancer drugs called
anti-PD-1 antibodies for treatment of gastric cancer and other
diseases
    ** Up to last close, stock down 7.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))